Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors

Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors

Bibliographic Details
Main Authors:	Mar Riveiro-Barciela, Enriqueta Felip, María E. Suarez-Almazor
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Medicine
Subjects:	immunotherapy toxicity cancer oncology—discipline special populations
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.1104382/full

Similar Items

Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management
by: Mar Riveiro-Barciela, et al.
Published: (2022-10-01)

The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate
by: Laia Aceituno, et al.
Published: (2022-07-01)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
by: Vanina Vani, et al.
Published: (2020-04-01)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors
by: Nienke A. de Glas, et al.
Published: (2021-06-01)

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
by: Giuseppe Bronte, et al.
Published: (2023-08-01)

Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider
by: Brittany A. Klein, et al.
Published: (2022-08-01)

Immune-related adverse events from immune checkpoint inhibitors in pediatric patients: A literature review and case series
by: Margaret Cupit-Link, MD, et al.
Published: (2023-12-01)

Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis
by: Maria Paula Furtado Santos, et al.
Published: (2022-12-01)

Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017‒2020
by: Marta Bes, et al.
Published: (2022-01-01)

Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases
by: Jessica Tsukamoto, et al.
Published: (2018-10-01)

Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors
by: Maria-Carlota Londoño, et al.
Published: (2020-11-01)

Clinical Diagnosis and Treatment Recommendations for Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor
by: Xiaoxiao GUO, et al.
Published: (2019-10-01)

The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients’ Outcomes
by: Hamzah Abu-Sbeih, et al.
Published: (2018-07-01)

The gut microbiota and immune checkpoint inhibitors
by: Audrey Humphries, et al.
Published: (2018-09-01)

Editorial: Reducing adverse effects of cancer immunotherapy
by: Daniele Maria-Ferreira, et al.
Published: (2024-02-01)

The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
by: Sebastian Bruera, et al.
Published: (2022-08-01)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
by: Justin Tong, et al.
Published: (2022-10-01)

Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D
by: Adriana Palom, et al.
Published: (2022-10-01)

Rheumatic and Musculoskeletal Adverse Events with Immune Checkpoint Inhibitors: Data from the United States Food and Drug Administration Adverse Event Reporting System
by: Xerxes N Pundole, et al.
Published: (2019-07-01)

Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
by: Haoran Li, et al.
Published: (2022-05-01)

Diagnostic Value of the International Society of Cardio‐Oncology Definition for Suspected Immune Checkpoint Inhibitor–Associated Myocarditis
by: Francois Deharo, et al.
Published: (2023-04-01)

HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment
by: Sophia Gandarillas, et al.
Published: (2024-01-01)

Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II
by: Deborah L. Burnett, et al.
Published: (2023-10-01)

Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients
by: Iuliia Kovalenko, et al.
Published: (2024-01-01)

Immunotherapy in Older Patients with Cancer: A Narrative Review
by: Smith A, et al.
Published: (2024-01-01)

Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer
by: Jennifer Dine, et al.
Published: (2017-01-01)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
by: Marcus Wölffer, et al.
Published: (2022-01-01)

Por una sociología del espacio editorial: el caso de César Aira y Beatriz Viterbo
by: María Belén Riveiro
Published: (2021-01-01)

La técnica PERT en la programación y control de proyectos
by: Alberto Barciela
Published: (1990-06-01)

New approaches to treating cancer using immune-checkpoint blockade
by: Fellermeyer, M
Published: (2023)

Immune checkpoint inhibitor therapy in advanced cervical cancer: Deepened response with prolonged treatment and repeat response to re-initiation of therapy
by: Jennifer Wolf, et al.
Published: (2023-08-01)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
by: Yanting Zhou, et al.
Published: (2023-06-01)

Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer
by: Francesco Fiorica, et al.
Published: (2021-05-01)

LINK-B: study protocol of a retrospective and prospective project for identification and linkage to care of people living with hepatitis B in a large health area of Barcelona
by: Ariadna Rando, et al.
Published: (2022-12-01)

Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience
by: Michael C. Tjong, et al.
Published: (2022-01-01)

Immune checkpoint inhibitor-associated cardiovascular toxicities: A review
by: Guihong Liu, et al.
Published: (2024-03-01)

Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events
by: Jaume Mora, et al.
Published: (2023-01-01)

Implementasi Shalat Tahajud dalam Pembentukan Kedisiplinan Santri di Pondok Pesantren Putri Roudhotul Qur’an Cukir Jombang
by: Muhammad Arif Ridwan, MAR
Published: (2017-08-01)

Evaluation of cardiovascular comorbidity in cancer patients and analysis of potential risk factors for cardiovascular complications of checkpoint inhibitor therapy
by: E. A. Kushnareva, et al.
Published: (2022-01-01)

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
by: Remo Poto, et al.
Published: (2022-03-01)